论文部分内容阅读
目的:探讨醒脑解郁胶囊联合利培酮治疗卒中后抑郁症临床疗效。方法:将75例患者随机分为3组,中药加奥氮平组、单纯中药组、西药对照组,给予不同处理。观察HAMD量表评分和神经功能缺损评分。结果:治疗后第21天中药加利培酮组治疗后HAMD评分和神经功能缺损评分与治疗后单纯中药组、西药对照组比较,差异有统计学意义(P<0.05)。结论:醒脑解郁胶囊联合利培酮治疗卒中后抑郁症,既能有效减轻患者精神症状,又有利于患者神经功能恢复,疗效优于单纯中药治疗和单纯百忧解治疗。
Objective: To investigate the clinical effect of Xingnao Jieyu capsule combined with risperidone on post-stroke depression. Methods: Seventy-five patients were randomly divided into three groups: Chinese medicine plus olanzapine group, simple Chinese medicine group and western medicine control group, which were given different treatment. HAMD scale scores and neurological deficit scores were observed. Results: On the 21st day after treatment, the HAMD score and neurological deficit score of Chinese medicine plus risperidone group after treatment were significantly different from those of traditional Chinese medicine group and western medicine control group (P <0.05). Conclusion: Xingnao Jieyu capsule combined with risperidone in the treatment of post-stroke depression can not only effectively alleviate the patients’ mental symptoms, but also help to restore the neurological function of patients. The curative effect is superior to that of traditional Chinese medicine and only Prozac treatment.